# US 2020/0368170 A1 · A lipid nanoparticle composition and a pharmaceutical composition for treating a hematoproliferative disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368170 A1
- Document ID: US20200368170A1
- Status: Published application
- Kind: A1
- Application number: 16/635,858
- Filed: 2018-07-31
- Published: 2020-11-26
- Earliest claimed: 2017-07-31
- Assignees: Jiangsu Genalza Biotech Co., Ltd.
- Applicants: Jiangsu Genalza Biotech Co., Ltd.
- Inventors: Hao Feng; Yibai Li
- Web page: https://patentgrep.com/patent/US20200368170A1

## CPC

- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a lipid nanoparticle composition and a pharmaceutical composition thereof used in treating a hematoproliferative disorder. Specifically, the lipid nanoparticle composition may include cytarabine, an anthracycline, and lipid nanoparticles, wherein cytarabine and the anthracycline are co-encapsulated in the lipid nanoparticles, the lipid nanoparticles comprise a charged lipid stabilizer, and the effective mean particle size of the lipid nanoparticles is less than 400 nm.

## Claims

### Claim 1

A lipid nanoparticle composition, comprising:
cytarabine, an anthracycline, and lipid nanoparticles, wherein
cytarabine and the anthracycline are co-encapsulated in the lipid nanoparticles,
the lipid nanoparticles comprise a charged lipid stabilizer, and
the effective mean particle size of the lipid nanoparticles is less than 400 nm.

### Claim 2 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the anthracycline is annamycin and/or 4-demethoxydaunorubicin.

### Claim 3 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein cytarabine further comprises a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the anthracycline further comprises a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the molar ratio of cytarabine to the anthracycline is from 30:1 to 50:1.

### Claim 6 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the effective mean particle size of the lipid nanoparticles is less than 200 nm.

### Claim 7 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the components of the lipid nanoparticles comprise at least one phosphatidylcholine, a charged lipid stabilizer, and a conditioning agent of phospholipid membrane fluidity.

### Claim 8 (depends on 1)

The lipid nanoparticle composition of claim 1, wherein the charged lipid stabilizer is at least one selected from the group consisting of methoxypolyethylene glycol-distearylphosphatidylethanolamine and phosphatidylglycerol.

### Claim 9 (depends on 8)

The lipid nanoparticle composition of claim 8, wherein the phosphatidylglycerol is selected from any one of the following or a mixture of several of the following: dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, and distearylphosphatidylglycerol.

### Claim 10 (depends on 7)

The lipid nanoparticle composition of claim 7, wherein the phosphatidylcholine is any one selected from egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleylphosphatidylcholine, and dimyristoylphosphatidylcholine.

### Claim 11 (depends on 7)

The lipid nanoparticle composition of claim 7, wherein the conditioning agent of phospholipid membrane fluidity is cholesterol.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the lipid nanoparticle composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the lipid nanoparticle composition of claim 1 and a pharmaceutically acceptable carrier, and the pharmaceutical composition comprises 1%-7% by weight of cytarabine, 0.1%-3% by weight of the anthracycline, 5%-20% by weight of hydrogenated soybean phosphatidylcholine or distearoylphosphatidylcholine, 0.5%-5% by weight of methoxypolyethylene glycol-distearylphosphatidylethanolamine, 0.5%-5% by weight of cholesterol, and 70%-90% by weight of sucrose.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, comprising 2%-5% by weight of cytarabine, 0.1%-1.5% by weight of the anthracycline, 6%-12% by weight of hydrogenated soybean phosphatidylcholine or distearoylphosphatidylcholine, 1%-3% by weight of methoxypolyethylene glycol-distearylphosphatidylethanolamine, 1%-3% by weight of cholesterol, and 75%-85% by weight of sucrose.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the lipid nanoparticle composition of claim 1 and a pharmaceutically acceptable carrier, and the pharmaceutical composition comprises 1%-7% by weight of cytarabine, 0.1%-3% by weight of the anthracycline, 5%-20% by weight of hydrogenated soybean phosphatidylcholine or distearoylphosphatidylcholine, 0.5%-10% by weight of distearylphosphatidylglycerol, 0.5%-5% by weight of cholesterol, and 65%-90% by weight of sucrose.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15 comprising 2%-5% by weight of cytarabine, 0.1%-1.5% by weight of the anthracycline, 12%-18% by weight of hydrogenated soybean phosphatidylcholine or distearoylphosphatidylcholine, 2%-5% by weight of distearylphosphatidylglycerol, 0.5%-2% by weight of cholesterol,. and 70%-80% by weight of sucrose.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the lipid nanoparticles are in liquid form or lyophilized form.

### Claim 18

A method of treating a hematoproliferative disorder, comprising administrating an effective amount of the lipid nanoparticle composition of claim to a subject in need thereof; wherein
the hematoproliferative disorder is at least one of leukemia, malignant lymphoma, or multiple myeloma.

### Claim 19

(canceled)

### Claim 20 (depends on 13)

The pharmaceutical composition of claim 13, wherein the lipid nanoparticles are in liquid form or lyophilized form.

### Claim 21 (depends on 15)

The pharmaceutical composition of claim 15, wherein the lipid nanoparticles are in liquid form or lyophilized form.

### Claim 22 (depends on 12)

A method of treating a hematoproliferative disorder, comprising administrating an effective amount of the pharmaceutical composition of claim 12 to a subject in need thereof; wherein
the hematoproliferative disorder is at least one of leukemia, malignant lymphoma, or multiple myeloma.

### Claim 23 (depends on 13)

A method of treating a hematoproliferative disorder, comprising administrating an effective amount of the pharmaceutical composition of claim 13 to a subject in need thereof; wherein
the hematoproliferative disorder is at least one of leukemia, malignant lymphoma, or multiple myeloma.

### Claim 24 (depends on 15)

A method of treating a hematoproliferative disorder, comprising administrating an effective amount of the pharmaceutical composition of claim 15 to a subject in need thereof; wherein
the hematoproliferative disorder is at least one of leukemia, malignant lymphoma, or multiple myeloma.
